Indeferimento
#9.2
05/27/2025
RPI 2838
Application data
Number
112020002967Type
Filing
Publication
PCT
US2018046760 The application was refused by the INPI on 05/27/2025. The invention was never patented.
Talk to a specialistLatest action published by the INPI: 05/27/2025. We update with every new RPI gazette, published weekly.
Applicants
SPRUCE BIOSCIENCES, INC.
US
Inventors
A. H. (pessoa física)
US
H. G. (pessoa física)
US
M. H. (pessoa física)
US
IPC Classification
Priority claims
US
62/545,406 · 08/14/2017
Abstract
A presente invenção fornece novas composições farmacêuticas que compreendem -(4-cloro-2-(morfolin-4-il)tiazol-5-il)-7-(1-etilpropil)-2,5-dimetilpirazolo(1,5-a)pirimidina e métodos de utilização dos mesmos para o tratamento da hiperplasia adrenal congênita (CAH).
Publications in the Brazilian Industrial Property Gazette (RPI).
#9.2
05/27/2025
RPI 2838
#7.1
02/04/2025
RPI 2822
#25.7
09/05/2023
RPI 2748
#6.23
08/16/2022
RPI 2693
#15.35
11/03/2021
RPI 2652
#1.3
08/11/2020
RPI 2588
#1.1
02/27/2020
RPI 2564
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.